Eiger BioPharmaceuticals Inc

Eiger BioPharmaceuticals Inc

  • Price (USD)11.28
  • Today's Change-1.14 / -9.18%
  • Shares traded260.31k
  • 1 Year change10.70%
  • Beta1.5094
Data delayed at least 15 minutes, as of Aug 11 2020 21:00 BST.
More ▼

Profile data is unavailable for this security.

About the company

Eiger BioPharmaceuticals Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing drugs for serious diseases. Its product candidate pipeline includes programs, including Lonafarnib (LNF), Peginterferon Lambda (lambda), LNF in Progeria and Progeroid Laminopathies (PL), Avexitide. LNF is an orally bioavailable, farnesylation inhibitor in Phase-III clinical trials for Hepatitis Delta Virus (HDV) infection. Lambda is a late-stage, type III interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. It is also developing lonafarnib for treatment of Progeria and Progeroid Laminopathies. Avexitide is a peptide that it is being developed as a treatment for Post-Bariatric Hypoglycemia (PBH). Avexitide is also being developed for Congenital Hyperinsulinism (CHI).

  • Revenue in USD (TTM)0.00
  • Net income in USD-66.10m
  • Incorporated2012
  • Employees28.00
  • Location
    Eiger BioPharmaceuticals Inc2155 Park BlvdPALO ALTO 94306-1543United StatesUSA
  • Phone+1 (650) 279-9845
  • Fax+1 (650) 618-1621
  • Websitehttp://www.eigerbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Trevena Inc31.00k-26.96m335.48m24.00--7.20--10,821.82-0.2773-0.27730.00030.43490.0005----1,291.67-41.00-55.42-47.58-65.70-----86,961.29-1,782.92---237.440.00---99.46--19.21------
Harpoon Therapeutics Inc9.71m-55.42m336.40m76.00--4.67--34.64-2.27-2.270.39792.870.0548----159,180.30-31.30---36.87-------570.75------0.00--21.62---103.07------
Wave Life Sciences Ltd12.52m-195.52m336.95m301.00------26.92-5.66-5.660.36210.09470.0425--0.500741,584.72-66.33-54.34-110.16-71.05-----1,562.01-1,455.31----0.00--10.89---32.04--46.03--
Imara Inc0.00-34.34m345.61m16.00--3.15-----5.48-5.480.006.35------0.00--------------------0.00-------106.96------
CytomX Therapeutics Inc85.19m-62.63m351.98m158.00--5.98--4.13-1.38-1.381.871.270.2109--16.69539,189.90-15.51-24.00-19.87-29.18-----73.52-165.55----0.00---3.3862.48-20.84--16.03--
Precision BioSciences Inc23.77m-87.93m355.25m225.00--3.06--14.94-2.62-2.620.56582.240.1248--4.75119,467.30-46.16---61.52-------369.86------0.00--104.34---101.74------
PDL BioPharma Inc54.06m-93.50m362.34m75.00--0.6883--6.70-0.7845-0.90350.45734.620.06834.043.20720,746.70-11.876.98-12.557.772.55---173.9026.1712.95--0.023531.21-72.36-37.65-2.25---50.29--
Eiger Biopharmaceuticals Inc0.00-66.10m363.20m28.00--5.78-----2.68-2.680.002.150.00----0.00-56.00-73.03-63.98-84.77-----------33.180.3448-------34.09--175.37--
MannKind Corporation61.94m-44.21m364.39m233.00------5.88-0.2126-0.21260.2973-0.7850.67117.4914.85265,824.00-47.90-74.49-222.94--52.9533.95-71.37-179.881.01-3.27----126.28--40.32---36.11--
Osmotica Pharmaceuticals PLC231.55m-267.30m366.62m379.00--2.36--1.58-5.09-5.094.302.440.37014.265.17610,960.40-42.72---48.75--55.51---115.44--2.910.43570.6512---8.98---146.99------
Magenta Therapeutics Inc0.00-83.32m367.69m72.00--2.11-----2.13-
AMAG Pharmaceuticals, Inc.320.61m-368.86m372.20m440.00--1.40--1.16-10.88-10.889.457.700.35113.573.38728,656.80-40.39-9.03-50.70-10.3964.7368.85-115.05-38.341.37-5.070.5159---30.8521.38-175.46--235.56--
Ideaya Biosciences Inc0.00-44.45m377.07m43.00--2.81-----2.20-
Merus NV28.48m-69.11m382.97m87.00--3.82--13.45-2.59-2.591.083.450.126--16.11327,324.60-30.58-31.83-36.38-37.05-----242.69-236.60----0.00---18.8878.29-94.81--65.67--
Ovid Therapeutics Inc0.00-76.19m390.94m60.00--13.37-----1.55-1.550.000.5340.00----0.00-151.97-70.15-199.19-76.80------------0.00-------16.32--121.38--
Data as of Aug 11 2020. Currency figures normalised to Eiger BioPharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

39.38%Per cent of shares held by top holders
HolderShares% Held
683 Capital Management LLCas of 31 Mar 20202.04m8.14%
BlackRock Fund Advisorsas of 31 Mar 20201.66m6.64%
Broadfin Capital LLCas of 31 Dec 20191.24m4.93%
The Vanguard Group, Inc.as of 31 Mar 20201.22m4.86%
Citadel Advisors LLCas of 31 Mar 2020853.28k3.41%
Cormorant Asset Management LPas of 31 Mar 2020815.13k3.25%
Mangrove Partnersas of 31 Mar 2020683.83k2.73%
Knoll Capital Management LPas of 31 Mar 2020475.24k1.90%
SSgA Funds Management, Inc.as of 31 Mar 2020459.55k1.83%
J. Goldman & Co. LPas of 31 Mar 2020420.05k1.68%
More ▼
Data from 31 Dec 2019 - 31 Mar 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.